Short-term efficacy of early percutaneous cholecystostomy for pancreatitis and factors associated with recurrence and mortality

Table 5 Pre-percutaneous cholecystostomy comparison between the nonrecurrent and recurrent groups, n (%)

Variables	Nonrecurrent group (n = 37)	Recurrent group (n = 10)	Single factor analysis	Multi-factor analysis
			P value	P value [OR (95%CI)]
Age (years)	66.14 ± 17.1	42.5 ± 21	< 0.001a	0.047 [0.937 (0.878-0.999)]
Sex			0.897
Male	19 (51.4)	6 (60)
Female	18 (48.6)	4 (40)
BMI	25.03 ± 2.99	26.6 ± 3.5	0.164
RAC classification			0.897
Moderately severe	19 (51.4)	6 (60)
Severe	18 (48.6)	4 (40)
Bile duct stone type			0.379
Positive stones	27 (73)	4 (40)
Negative stones	17 (45.9)	6 (60)
Day of hospitalization (days)	15.7 ± 10.31	19.9 ± 6.82	0.232
Fever (temperature ≥ 37.3 °C)	20 (54.1)	4 (40)	0.117
WBC (× 109/L)	13.09 (10.85-16.56)	15.54 (10.01-17.08)	0.697
NEU (%)	87.9 (82.8-91.15)	86.35 (79.25-89.23)	0.176
ALT (U/L)	53.3 (23.85-129.45)	29 (21-105.83)	0.311
GGT (U/L)	108 (51-280)	97 (46.25-174.25)	0.659
TBIL (μmol/L)	25.5 (15.85-68.8)	22.9 (17.45-40.85)	0.467
AMS (U/L)	398 (156.5-983)	420 (129.5-1327.25)	0.938
Gallbladder width (cm)	3.6 (3.1-4)	3.45 (2.98-3.93)	0.474
CTSI	3 (1.5-3.5)	4 (3-5)	0.043a	0.209 [1.596 (0.770-3.311)]
CCI	4 (3-5)	2.5 (2-4)	0.023a	0.925 [1.036 (0.491-2.188)]
Congestive heart failure	2 (5.4)	0	1
Diabetes mellitus (no comorbidities)	8 (21.6)	5 (50)	0.167
Solid tumors (no metastases)	2 (4.3)	0	1
Cerebrovascular disease	7 (18.9)	0	0.322
History of pancreatitis	7 (18.9)	4 (40)	0.329
Hypertension	18 (48.6)	4 (40)	0.897

^aP < 0.05.

PC: Percutaneous cholecystostomy; BMI: Body mass index; RAC: Revised Atlanta classification; WBC: White blood cell; NEU: Neutrophil; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; AMS: Amylase; CTSI: Computed tomography severity index; CCI: Charlson Comorbidity Index; OR: Odds ratio; CI: Confidence interval.